• Gilead en Galapagos kondigen positieve Europese CHMP opinie aan voor Jyseleca® (Filgotinib) voor de behandeling van volwassenen met matige tot ernstige reumatoïde artritis

    Friday July 24th 2020

  • Aligos Therapeutics and KU Leuven announce collaboration for the development of a therapeutic candidate targeting Coronavirus

    Thursday July 2nd 2020

  • US multicenter study shows Idylla™ allows rapid and accurate mutation testing results across different laboratory settings

    Friday June 26th 2020

  • eTheRNA raises EUR 34 million in Series B financing to accelerate multiple mRNA therapeutic development programs through to clinical proof of concept

    Wednesday June 17th 2020

  • Johnson & Johnson announces acceleration of its COVID-19 vaccine candidate

    Thursday June 11th 2020

  • New analyses of Phase 2 Equator Clinical Program support durable efficacy of Filgotinib in Psoriatic Arthritis

    Monday June 8th 2020

  • Filgotinib demonstrates durable efficacy and consistent safety profile at 52 weeks in Finch 1 and 3 studies in rheumatoid arthritis

    Thursday June 4th 2020

  • Celyad provides update on allogeneic CAR-T franchise

    Tuesday June 2nd 2020

  • Your news here?

  • argenx announces positive topline results from Phase 3 ADAPT Trial of Efgartigimod in patients with Generalized Myasthenia Gravis

    Tuesday May 26th 2020

  • Gilead and Galapagos announce positive topline results of Phase 2B/3 trial of Filgotinib

    Thursday May 21st 2020

  • Bone Therapeutics treats first patients in pivotal JTA-004 phase III knee osteoarthritis study

    Monday May 18th 2020


Strategic Partners